英夫利昔单抗联合低分子肝素钙对川崎病患儿凝血功能及血清炎症因子水平的影响  

Effects of Infliximab combined with low molecular weight heparin calcium on coagulation function and serum inflammatory factors in children with Kawasaki disease

作　　者：刘培佳 Liu Pei-jia(Department of Pediatrics,Yuzhou People's Hospital,Yuzhou 452570,Henan,China)

机构地区：[1]禹州市人民医院儿科,河南禹州452570

出　　处：《四川生理科学杂志》2025年第1期129-131,165,共4页

摘　　要：目的:分析英夫利昔单抗联合低分子肝素钙对川崎病患儿凝血功能及血清炎症因子水平的影响。方法:选取2021年1月至2023年12月期间于禹州市人民医院接受治疗的98例川崎病患儿作为研究对象。按照是否联用英夫利昔单抗治疗将患儿分为研究组和对照组,各49例。收集两组临床资料,比较两组临床疗效、临床症状改善时间、凝血功能指标[纤维蛋白原(Fibrinogen,FIB)、凝血酶原时间(Prothrombin time,PT)、活化部分凝血活酶时间(Activated partial thromboplastin time,APTT)、凝血酶时间(Thrombin time,TT)]、血清炎症因子[C反应蛋白(C-reactive protein,CRP)、肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)、白细胞介素-6(Interleukin-6,IL-6)、白细胞介素-8(Interleukin-8,IL-8)]水平以及不良反应发生率。结果:研究组治疗总有效率明显高于对照组(P<0.05)。治疗后,研究组发热、黏膜充血、手足硬肿、全身皮疹的改善时间明显短于对照组(P<0.05);研究组TT、APTT、PT均较对照组明显提高,FLB水平明显降低(P<0.05);研究组CRP、TNF-α、IL-6、IL-8水平均明显低于对照组(P<0.05)。两组的不良反应发生率无明显差异(P>0.05)。结论:英夫利昔单抗联合低分子肝素钙治疗川崎病可缓解临床症状,改善凝血功能,减轻机体炎症,且安全性较高。Objective:To analyze the effects of infliximab combined with low molecular weight heparin calcium on the coagulation function and serum inflammatory factor levels in children with Kawasaki disease.Methods:A total of 98 children with Kawasaki disease treated in Yuzhou people's Hospital from January 2021 to December 2023 were selected as the research objects.The children were divided into study group and control group according to whether they were treated with infliximab or not,49 cases in each group.Clinical data were collected from both groups,and the clinical efficacy,time to clinical improvement,coagulation function indicators[fibrinogen(FIB),Prothrombin time(PT),Activated partial thromboplastin time(APTT),Thrombin time(TT)],serum inflammatory factors[C-reactive protein(CRP),Tumor necrosis factor-α(TNF-α),Interleukin-6(IL-6),IL-8],and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the treatment group was significantly higher than that of the control group(P<0.05).After treatment,the improvement time of fever,mucosal congestion,hand and foot induration,and generalized rash in the study group was significantly shorter than that in the control group(P<0.05).The TT,APTT and PT levels in the study group were significantly higher than those in the control group,while the FLB level was significantly lower(P<0.05).The levels of CRP,TNF-α,IL-6 and IL-8 in the study group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Infliximab combined with low molecular weight heparin calcium in the treatment of Kawasaki disease can alleviate clinical symptoms,improve coagulation function,reduce inflammation,and have high safety.

关 键 词：英夫利昔单抗 低分子肝素钙 川崎病 凝血功能 血清炎症因子 

分 类 号：R446.11[医药卫生—诊断学] R725.9[医药卫生—临床医学]